Shares of Nabriva Therapeutics plc – (NASDAQ:NBRV) have been assigned an average rating of “Buy” from the nine research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $18.71.
A number of equities research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Nabriva Therapeutics in a research note on Thursday, November 16th. Morgan Stanley assumed coverage on Nabriva Therapeutics in a research note on Wednesday, January 17th. They set an “overweight” rating and a $10.00 price target for the company. Finally, ValuEngine downgraded Nabriva Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd.
Several institutional investors and hedge funds have recently bought and sold shares of NBRV. Stanley Laman Group Ltd. purchased a new stake in shares of Nabriva Therapeutics during the 4th quarter worth about $154,000. Commonwealth Equity Services Inc raised its stake in shares of Nabriva Therapeutics by 109.7% during the 3rd quarter. Commonwealth Equity Services Inc now owns 26,760 shares of the biotechnology company’s stock worth $219,000 after purchasing an additional 14,000 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Nabriva Therapeutics in the 3rd quarter valued at approximately $293,000. Cubist Systematic Strategies LLC bought a new position in shares of Nabriva Therapeutics in the 3rd quarter valued at approximately $348,000. Finally, Virtu Financial LLC bought a new position in shares of Nabriva Therapeutics in the 4th quarter valued at approximately $429,000. 55.72% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Nabriva Therapeutics plc – (NBRV) Receives Average Rating of “Buy” from Analysts” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/03/14/nabriva-therapeutics-plc-nbrv-receives-average-rating-of-buy-from-analysts.html.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.